Moderna Inc. closed up 14.36 percent at $158.83 on Tuesday, making it the single largest gainer among S&P 500 constituents on a day when the index itself moved less than half a percent. The stock traded 45.9 million shares, more than four times its recent average, as investors continued digesting late-stage clinical data on the company's personalized melanoma vaccine.
The move was the latest chapter in a rally that began the previous week, when Moderna and development partner Merck & Co. announced that their experimental therapy, intismeran autogene, had hit its primary and key secondary survival endpoints in a Phase 3 trial. That initial readout, published August 19, sent Moderna shares climbing through the session, from a previous close near $62.96 to a close of $174.38, a gain of 176.97 percent.
Melanoma is among the deadliest forms of skin cancer. It originates in melanocytes, the cells responsible for skin pigment, and is defined by their uncontrolled growth, according to the Mayo Clinic. Patients whose melanoma is caught and surgically removed before it spreads still face a meaningful risk of recurrence, which is the population the INTerpath-001 trial specifically targeted.
What the trial showed
The Phase 3 study, known as INTerpath-001, enrolled more than 1,100 patients with high-risk or advanced melanoma who had already undergone surgery to remove their detectable cancer. Researchers tested whether adding intismeran autogene, an individualized mRNA vaccine, to Merck's immunotherapy Keytruda would outperform Keytruda alone at keeping the cancer from returning.
It did. The combination significantly extended the time patients lived without their melanoma recurring, according to Moderna and Merck, and also reduced the rate at which the disease spread to other organs. The companies reported no new safety issues associated with the combination therapy.
The results build on earlier Phase 2 data from the same drug pairing, which showed a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant metastasis or death compared with Keytruda alone. Merck referenced those earlier figures directly in its most recent release, framing the Phase 3 results as confirmation of what the smaller trial had suggested.
Moderna and Merck said they plan to present the full, unpublished data set to regulators at an upcoming international medical meeting, a step that typically precedes a formal submission for regulatory approval.
How the therapy works
Intismeran autogene is a personalized cancer vaccine, meaning it is manufactured individually for each patient rather than produced as a single standardized product. The vaccine is designed using the specific genetic mutations found in a patient's own tumor, an approach intended to train the immune system to recognize and attack cancer cells that carry those particular mutations.
That individualized approach is central to why analysts and executives have described the trial results as more significant than a single successful drug. Every tumor carries a distinct set of mutations, even among patients diagnosed with the same type of cancer, which is why a therapy built around each patient's unique tumor profile is seen as a fundamentally different model than conventional one-size-fits-all cancer treatment.
Moderna Chief Executive Stéphane Bancel called the melanoma results "a pivotal moment for the field of cancer research," tying the data to years of work applying the company's mRNA delivery technology, first proven at scale through its COVID-19 vaccine, to oncology.
The market reaction, in two parts
Moderna's stock move has come in two distinct waves. The first, on August 19, was the reflexive shock of the data itself. Shares jumped $91.52, or 145 percent, to $154.48 in morning trading and touched an intraday high of $163 before continuing to climb into the close, finishing the day up 176.97 percent at $174.38. That closing price left the company with a market capitalization of roughly $25 billion. Trading volume that day reached 185.1 million shares, about 1,819 percent above the stock's three-month average.
The second wave, still playing out, has been driven by Wall Street's institutional response to the data. Bank of America upgraded Moderna from Underperform to Neutral and raised its price target from $40 to $170, with analyst Alec Stranahan calling the readout "a watershed moment for Moderna" that allows the company to diversify away from infectious disease and eases persistent concerns about its cash position. BofA raised its unadjusted global peak sales estimate for intismeran to $54 billion and increased its assumed probability of success in adjuvant melanoma to 85 percent.
William Blair moved its rating to Outperform, citing the melanoma program's potential to diversify Moderna's revenue base away from COVID-era products. Morgan Stanley analyst Terence Flynn kept a Hold rating but raised his price target from $39 to $89, though he cautioned that a roughly $20 billion risk-adjusted peak sales estimate for intismeran may already be reflected in the stock price. In the days following the initial trial data, Wall Street's consensus rating on Moderna stood at 12 Holds, two Buys and one Sell.
Tuesday's 14.36 percent gain reflects that second wave: continued repricing by analysts and investors working through the implications of the trial data, rather than a reaction to new clinical results. The stock's year-to-date performance now stands at roughly 392 percent.
A market-wide ripple
Merck's shares also moved on the initial data, rising $14.35, or 10.6 percent, on August 19 to close at $149.52. The disparity in percentage terms between the two stocks reflects their difference in size: Merck entered the week with a market capitalization near $333 billion, more than ten times Moderna's roughly $25 billion, meaning the same trial data registered as a modest move for one company and an era-defining one for the other.
Moderna's gain was also the standout move within the S&P 500 index itself on Tuesday, a session in which the broader index added just 24.42 points, or 0.32 percent, to close at 7,677.28. Exchange data show that 97.5 percent of the day's advance was already priced in by the opening bell, with the index spending the rest of the session in a narrow, roughly 35-point range that ended close to where it began. Against that largely static backdrop, Moderna's double-digit percentage move stood out as one of the only significant single-stock stories of the day.
Analysts have cautioned that the size of Tuesday's move should not be read as confirmation that the melanoma data alone justifies the stock's new valuation. Much of Moderna's rally already reflects expectations that intismeran could eventually succeed across multiple tumor types beyond melanoma, not solely the results disclosed so far. The company and Merck are currently studying the same vaccine platform in ongoing trials for non-small cell lung cancer, bladder cancer and renal cell carcinoma, any of which could produce its own market-moving readout in the months ahead.
What's next
More than 234,680 new melanoma cases are expected to be diagnosed in the United States in 2026, according to the Skin Cancer Foundation, and the disease is projected to kill more than 8,500 Americans this year. Any therapy that meaningfully reduces recurrence in high-risk patients would address one of the more consequential unmet needs in oncology, which is part of why the trial data has drawn attention well beyond Moderna's own shareholder base.
The next concrete catalyst is regulatory: Moderna and Merck have said they intend to present the complete Phase 3 data set at an upcoming international medical meeting, a step that typically precedes a formal filing with regulators. Until that filing is made and reviewed, intismeran autogene remains an investigational therapy, not an approved treatment, and the current wave of price-target increases and rating changes reflects analysts' expectations for that regulatory path rather than a completed approval.
